We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Arvinas, Inc. (ARVN) Moves 17.5% Higher: Will This Strength Last?
Read MoreHide Full Article
Arvinas, Inc. (ARVN - Free Report) shares ended the last trading session 17.5% higher at $28.78. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 5.7% gain over the past four weeks.
The sudden surge in Arvinas' stock price can be attributed to the momentum developed around the company's oncology pipeline. Last week, the company reported positive initial data from its phase I/II dose escalation and expansion study of ARV-766 in male patients with metastatic castration-resistant prostrate cancer (mCRPC). Per the data readout, signs of efficacy in late-line mCRPC patients were observed upon treatment with AR-766, along with a favorable tolerabilty profile. Arvinas is also currently developing another candidate, ARV-110, in a phase I/II study to treat mCPRC, with a reportedly different profile as compared to ARV-766. Furthermore, the company plans to initiate a phase III study on ARV-471, in partnership with Pfizer, in the treatment of ER+/HER2- breast cancer.
This company is expected to post quarterly loss of $1.67 per share in its upcoming report, which represents a year-over-year change of -26.5%. Revenues are expected to be $32.45 million, up 3.7% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Arvinas, Inc., the consensus EPS estimate for the quarter has been revised 0.8% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on ARVN going forward to see if this recent jump can turn into more strength down the road.
Arvinas, Inc. is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Gilead Sciences (GILD - Free Report) , finished the last trading session 0.3% lower at $77.86. GILD has returned -0.1% over the past month.
For Gilead, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $1.66. This represents a change of +5.1% from what the company reported a year ago. Gilead currently has a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Arvinas, Inc. (ARVN) Moves 17.5% Higher: Will This Strength Last?
Arvinas, Inc. (ARVN - Free Report) shares ended the last trading session 17.5% higher at $28.78. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 5.7% gain over the past four weeks.
The sudden surge in Arvinas' stock price can be attributed to the momentum developed around the company's oncology pipeline. Last week, the company reported positive initial data from its phase I/II dose escalation and expansion study of ARV-766 in male patients with metastatic castration-resistant prostrate cancer (mCRPC). Per the data readout, signs of efficacy in late-line mCRPC patients were observed upon treatment with AR-766, along with a favorable tolerabilty profile. Arvinas is also currently developing another candidate, ARV-110, in a phase I/II study to treat mCPRC, with a reportedly different profile as compared to ARV-766. Furthermore, the company plans to initiate a phase III study on ARV-471, in partnership with Pfizer, in the treatment of ER+/HER2- breast cancer.
This company is expected to post quarterly loss of $1.67 per share in its upcoming report, which represents a year-over-year change of -26.5%. Revenues are expected to be $32.45 million, up 3.7% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Arvinas, Inc., the consensus EPS estimate for the quarter has been revised 0.8% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on ARVN going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Arvinas, Inc. is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Gilead Sciences (GILD - Free Report) , finished the last trading session 0.3% lower at $77.86. GILD has returned -0.1% over the past month.
For Gilead, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $1.66. This represents a change of +5.1% from what the company reported a year ago. Gilead currently has a Zacks Rank of #3 (Hold).